<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hyaluronidases are endo-glycosidases that degrade both hyaluronan (<z:chebi fb="1" ids="16336">hyaluronic acid</z:chebi>) (HA) and <z:chebi fb="0" ids="37397">chondroitin sulfates</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1291490" disease_type="Disease or Syndrome" abbrv="MPS9">Deficiency of hyaluronidase</z:e> activity has been predicted to result in a phenotype similar to that observed in <z:e sem="disease" ids="C0026703" disease_type="Disease or Syndrome" abbrv="">mucopolysaccharidosis</z:e> (MPS) </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant <z:hpo ids='HP_0008155'>mucopolysacchariduria</z:hpo> to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity </plain></SENT>
<SENT sid="3" pm="."><plain>The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology </plain></SENT>
<SENT sid="4" pm="."><plain>The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity </plain></SENT>
<SENT sid="5" pm="."><plain>A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity </plain></SENT>
<SENT sid="6" pm="."><plain>Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA </plain></SENT>
<SENT sid="7" pm="."><plain>Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL) </plain></SENT>
<SENT sid="8" pm="."><plain>These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with <z:e sem="disease" ids="C0026706" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Sanfilippo disease</z:e>, one of the seven patients with <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e>, and one with hypophosphotemic <z:hpo ids='HP_0002748'>rickets</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> levels of serum Hyal-1 activities were found in patients with <z:e sem="disease" ids="C0026707" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Morquio disease</z:e>, <z:e sem="disease" ids="C0085131" disease_type="Disease or Syndrome" abbrv="">GM1 gangliosidosis</z:e>, <z:e sem="disease" ids="C0020725" disease_type="Disease or Syndrome" abbrv="ICD">I cell-disease</z:e>, 6 of the 7 patients with <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e>, <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's-syndrome</z:e> and <z:e sem="disease" ids="C0013720" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ehlers-Danlos syndrome</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>No patient totally lacked serum Hyal-1 activity </plain></SENT>
<SENT sid="11" pm="."><plain>Serum HA concentration was elevated in patients with Sanfilippo A and <z:e sem="disease" ids="C0020725" disease_type="Disease or Syndrome" abbrv="ICD">I-cell disease</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders </plain></SENT>
</text></document>